Show simple item record

dc.contributor.authorCardona, Andrés F
dc.contributor.authorRuiz-Patiño, Alejandro
dc.contributor.authorZatarain-Barron, Zyanya Lucia
dc.contributor.authorAriza, Santiago
dc.contributor.authorRicaurte, Luisa
dc.contributor.authorRolfo, Christian
dc.contributor.authorArrieta, Oscar
dc.date.accessioned2021-04-12T18:32:20Z
dc.date.available2021-04-12T18:32:20Z
dc.date.issued2021-03-10
dc.identifier.urihttp://hdl.handle.net/10713/15290
dc.description.abstractWe present the case of a 73-year-old male patient with a history of tobacco use who presented with a central nervous system mass that was confirmed to be a lung adenocarcinoma metastasis. High PD-L1 expression as well as negativity to other targetable drivers led to initiation of pembrolizumab monotherapy and ablative stereotactic radiation therapy on oligoresidual disease, achieving a complete response after 2 years of therapy. Following discontinuation of systemic treatment, the patient developed widespread desquamative plaques. A skin biopsy revealed subepidermal blistering and eosinophilic infiltration in conjunction with C3 and IgG depositions on the basement membrane, detected by immunofluorescence. A diagnosis of bullous pemphigoid was obtained, and systemic corticosteroids were administered with lesion progression. Infliximab was also administered without meaningful clinical improvement. Metronomic cyclophosphamide achieved a complete resolution of skin lesions and up to this day the patient continues with tumor control and is free of dermatological findings. In conclusion, bullous pemphigoid is a very rare dermatological adverse effect related with pembrolizumab treatment. Only two cases, including this one, have been reported, especially with this medication for the treatment of non-small cell lung cancer. With more reported cases, management strategies can be optimized even in the steroid refractory setting. © 2021 The Author(s).en_US
dc.description.urihttps://doi.org/10.1159/000514144en_US
dc.language.isoenen_US
dc.publisherS. Karger AGen_US
dc.relation.ispartofCase Reports in Oncologyen_US
dc.rightsCopyright © 2021 by S. Karger AG, Basel.en_US
dc.subjectAdverse eventsen_US
dc.subjectImmunotherapyen_US
dc.subjectPembrolizumaben_US
dc.subjectSkin reactionsen_US
dc.subjectToxicityen_US
dc.titleRefractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumaben_US
dc.typeArticleen_US
dc.identifier.doi10.1159/000514144
dc.identifier.pmid33776733
dc.source.volume14
dc.source.issue1
dc.source.beginpage386
dc.source.endpage390
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record